ABVX Trading Analysis - 10/23/2026 03:13 PM — TRU-SENTIMENT

News Headlines & Context:

Abivax (ABVX) is a clinical-stage biopharmaceutical company primarily focused on developing therapies for chronic inflammatory diseases, with its lead candidate obefazimod in Phase 3 for ulcerative colitis. Recent general-knowledge context includes:

• Abivax reported continued enrollment progress in its global Phase 3 ulcerative colitis program through mid-2026, with no major safety halt disclosed.
• Recent biotech-sector volatility tied to FDA regulatory commentary on accelerated approval pathways may have pressured small-cap names like ABVX.
• No confirmed near-term earnings catalyst found in general knowledge; fiscal year end per fundamentals is 2025-12-01, with no current target price consensus.
• Context: The embedded data shows a declining price trend from September highs near $119 to sub-$90 in October, consistent with a clinical-stage name lacking positive binary catalysts and facing broad sector de-risking.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for ABVX:

• Trailing EPS is -5.85, confirming the company is loss-making (clinical-stage). Trailing PE, forward PE, PEG, and price-to-book are all null — standard for pre-revenue biotech.
• Revenue growth, gross/operating/net margins, ROE, debt-to-equity, and free cash flow are null — no disclosed profitability or leverage metrics.
• Market cap is $7,638,918,160.00 with 87,272,000.00 shares outstanding; dividend yield is 0.00.
• Institutional ownership is low at 12.90%, indicating limited large-cap sponsor support.
• 52-week range: $69.81 low to $148.83 high; current price near $89.75 is in the lower third of the annual range.
• Historical volatility is 53.85%; average volume 1,316,000.00 vs 20-day avg 1,035,972.00.
• Analyst consensus and target mean price are null — no street anchor.
• Fundamentals (no earnings, low institutionality) align with the weak technical picture and balanced options sentiment; no fundamental strength offsets the downtrend.

Current Market Position:

Current price per indicators is $89.75 (2026-10-22 close). Minute bars show 2026-10-22 open $92.29, high $93.98, low $88.15, close $89.75 on volume 803,807. On 2026-10-23, last bars show 14:30 drop to $87.56 on 281,427 volume, then 14:45 at $87.53 — intraday weakness below prior close. Daily history shows steady decline from $118.64 (2026-09-11) to $89.75. Bollinger lower band $83.21 and 30-day low $84.11 are nearby support; 20-day SMA $91.03 and 5-day SMA $90.18 are resistance.

Technical Analysis:

SMA alignment is bearish: price $89.75 below SMA 5 ($90.18), SMA 20 ($91.03), and far below SMA 50 ($103.93) — no bullish crossover. RSI 45.08 shows neutral-to-soft momentum, not oversold. MACD -4.05 below signal -3.24 with negative histogram -0.81 indicates continued downside pressure. Price is between BB lower ($83.21) and middle ($91.03), no squeeze. 30-day range high $119.02, low $84.11; current price sits near bottom Quintile. Bearish structural bias.

True Sentiment Analysis (Delta 40-60 Options):

Options flow via tru-sentiment methodology (Delta 40-60 only):

Call Volume: $326,300.00 (58.1%) Put Volume: $235,775.00 (41.9%) Total: $562,075.00

Sentiment is Balanced per dataset (calls 58.1% / puts 41.9%, 37 true-sentiment contracts). Call dollar volume exceeds puts, but not at a directional threshold. Pure directional positioning suggests no strong near-term conviction; slight call tilt contradicts bearish technicals but is within balanced band. No divergence extreme — sentiment neutral while price weak.

Key Price Levels (observational only):